Another mechanism associated with the anti-tumor activity of EVs is the sensitization to chemotherapy; for example, AT-MSC-derived EVs have been modified to express miR-122, showing that the treatment of hepatocellular carcinoma cells with these EVs increases the sensitivity of tumor cells to sorafenib [129], since miR-122 inhibits the expression of the multidrug-resistance-related genes, such as ATP-binding cassette (ABC) transporters [130]. The gene discussed is ABCG2; the disease is neoplasm.